Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers
Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers Dec 15, 2020, 07:00 ET Read on Cision PR Newswire LP-184 preclinical studies reinforce the drug compound’s potential to effectively cross the blood-brain barrier with significant potency Continued progress in advancing glioblastoma [...]